- Home
- NRG vs GH Comparison
NRG vs GH Comparison
Compare NRG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRG | GH |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4B | 22.9B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NRG | GH |
|---|---|---|
| Price | $100.65 | $164.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 26 |
| Target Price | $185.50 | ★ $201.64 |
| AVG Volume (30 Days) | ★ 3.0M | 1.9M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $30,713,000,000.00 | $982,021,000.00 |
| Revenue This Year | $15.70 | $38.25 |
| Revenue Next Year | $3.81 | $35.37 |
| P/E Ratio | $37.74 | ★ N/A |
| Revenue Growth | 9.18 | ★ 32.88 |
| 52 Week Low | $94.56 | $64.00 |
| 52 Week High | $189.96 | $191.05 |
Technical Indicators
Market Signals| Indicator | NRG | GH |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 42.84 |
| Support Level | $94.56 | $153.88 |
| Resistance Level | $110.38 | $173.94 |
| Average True Range (ATR) | 4.16 | 7.44 |
| MACD | 1.28 | -2.27 |
| Stochastic Oscillator | 41.54 | 15.42 |
Price Performance
Historical ComparisonAbout NRG NRG Energy Inc.
NRG Energy is one of the largest retail energy providers in the US, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home-services customers. NRG also is one of the largest US independent power producers, with 26 gigawatts of coal, gas, and oil power generation capacity in Texas and the Eastern US. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.